nafamostat has been researched along with Polycystic Kidney, Autosomal Dominant in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Polycystic Kidney, Autosomal Dominant: Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maruyama, H | 1 |
| Miyakawa, Y | 1 |
| Gejyo, F | 1 |
| Arakawa, M | 1 |
1 other study available for nafamostat and Polycystic Kidney, Autosomal Dominant
| Article | Year |
|---|---|
Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient.
Topics: Anaphylaxis; Anticoagulants; Benzamidines; Equipment Failure; Female; Guanidines; Humans; Kidney Fai | 1996 |